AngioDynamics (NASDAQ:ANGO) SVP Lawrence Weiss Purchases 10,000 Shares

Key Points

• Lawrence Weiss, Senior Vice President of AngioDynamics, purchased 10,000 shares at an average price of $11.81, increasing his ownership by nearly 12% to a total of 93,597 shares valued at about $1.1 million.
• AngioDynamics reported quarterly earnings with EPS of ($0.10), surpassing analysts' estimates, and its revenue increased by 12.1% year-over-year, totaling $75.71 million.
• Analysts have varying ratings on AngioDynamics stock, with HC Wainwright setting a target price of $16.00 and Canaccord Genuity raising theirs to $18.00, while Weiss Ratings issued a "sell" rating.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) SVP Lawrence Weiss bought 10,000 shares of the stock in a transaction on Tuesday, October 21st. The shares were bought at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the purchase, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. This trade represents a 11.96% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

AngioDynamics Trading Up 2.9%

AngioDynamics stock traded up $0.34 during midday trading on Wednesday, hitting $12.04. The stock had a trading volume of 87,702 shares, compared to its average volume of 600,022. The firm's fifty day moving average is $10.58 and its two-hundred day moving average is $9.89. The company has a market capitalization of $496.21 million, a PE ratio of -15.42 and a beta of 0.78. AngioDynamics, Inc. has a 52-week low of $6.57 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The business had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The company's revenue was up 12.1% on a year-over-year basis. During the same period last year, the firm posted ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. As a group, equities research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Institutional Trading of AngioDynamics

A number of institutional investors have recently modified their holdings of ANGO. Divisadero Street Capital Management LP raised its holdings in shares of AngioDynamics by 253.7% in the second quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier's stock worth $33,683,000 after acquiring an additional 2,435,365 shares during the last quarter. Systematic Financial Management LP grew its position in AngioDynamics by 0.5% during the second quarter. Systematic Financial Management LP now owns 2,509,906 shares of the medical instruments supplier's stock valued at $24,898,000 after acquiring an additional 12,617 shares during the period. Vanguard Group Inc. lifted its stake in shares of AngioDynamics by 8.7% in the first quarter. Vanguard Group Inc. now owns 2,492,563 shares of the medical instruments supplier's stock worth $23,405,000 after acquiring an additional 199,944 shares in the last quarter. Armistice Capital LLC lifted its stake in shares of AngioDynamics by 140.1% in the first quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier's stock worth $19,663,000 after acquiring an additional 1,222,000 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of AngioDynamics in the first quarter worth about $10,803,000. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on ANGO shares. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research report on Wednesday, October 8th. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, October 3rd. Wall Street Zen cut shares of AngioDynamics from a "buy" rating to a "hold" rating in a research report on Saturday, October 4th. Finally, Lake Street Capital began coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price objective for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.33.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.